578 related articles for article (PubMed ID: 24528690)
1. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
2. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
3. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
5. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia.
Blair HA; Dhillon S
Am J Cardiovasc Drugs; 2014 Oct; 14(5):393-400. PubMed ID: 25234378
[TBL] [Abstract][Full Text] [Related]
7. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
8. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a Novel ω-3 Krill Oil Agent in Patients With Severe Hypertriglyceridemia: A Randomized Clinical Trial.
Mozaffarian D; Maki KC; Bays HE; Aguilera F; Gould G; Hegele RA; Moriarty PM; Robinson JG; Shi P; Tur JF; Lapointe JF; Aziz S; Lemieux P;
JAMA Netw Open; 2022 Jan; 5(1):e2141898. PubMed ID: 34989797
[TBL] [Abstract][Full Text] [Related]
10. Icosabutate for the treatment of very high triglycerides: A placebo-controlled, randomized, double-blind, 12-week clinical trial.
Bays HE; Hallén J; Vige R; Fraser D; Zhou R; Hustvedt SO; Orloff DG; Kastelein JJ
J Clin Lipidol; 2016; 10(1):181-91.e1-2. PubMed ID: 26892135
[TBL] [Abstract][Full Text] [Related]
11. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial.
Stroes ESG; Susekov AV; de Bruin TWA; Kvarnström M; Yang H; Davidson MH
J Clin Lipidol; 2018; 12(2):321-330. PubMed ID: 29289538
[TBL] [Abstract][Full Text] [Related]
13. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
Bays HE; Maki KC; McKenney J; Snipes R; Meadowcroft A; Schroyer R; Doyle RT; Stein E
Curr Med Res Opin; 2010 Apr; 26(4):907-15. PubMed ID: 20156032
[TBL] [Abstract][Full Text] [Related]
14. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
15. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
16. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Bays HE; Maki KC; Doyle RT; Stein E
Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283
[TBL] [Abstract][Full Text] [Related]
17. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels.
Berge K; Musa-Veloso K; Harwood M; Hoem N; Burri L
Nutr Res; 2014 Feb; 34(2):126-33. PubMed ID: 24461313
[TBL] [Abstract][Full Text] [Related]
18. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.
Davidson MH; Maki KC; Bays H; Carter R; Ballantyne CM
J Clin Lipidol; 2009 Oct; 3(5):332-40. PubMed ID: 21291831
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
20. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]